NCT05454358View on ClinicalTrials.gov

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

299

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

August 9, 2028

Study Completion Date

July 9, 2030

Conditions
Endometrial Cancer
Interventions
DRUG

Letrozole 2.5mg

Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy

Trial Locations (1)

Unknown

RECRUITING

Obstetrics and Gynecology Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Obstetrics & Gynecology Hospital of Fudan University

OTHER

lead

Fudan University

OTHER

NCT05454358 - Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | Biotech Hunter | Biotech Hunter